Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)

NCT06957691 is registered in ClinicalTrials.gov with Shehzad Basaria, M.D. as lead sponsor.

NCT NCT06957691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06957691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy (Fezo-ADT Trial)
Lead sponsor
Shehzad Basaria, M.D.
Phase
Phase 2
Overall status
Recruiting
Start date
January 14, 2026
Completion date
December 31, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

androgen ablative therapy of advanced hormone-dependent prostate carcinoma, androgen deprivation therapy, androgen-deprivation therapy, hot flashes, hot flushes, hot flushes and/or sweats, prostate adenocarcinoma, prostate cancer, prostate cancer (adenocarcinoma), prostate cancer metastatic disease, prostate cancer recurrent, prostate cancer with bone metastasis, prostate carcinoma, prostate neoplasm, vasomotor disturbance, vasomotor symptoms, vasomotor symptoms (vms), vasomotor symptoms as a sex hormone-dependent disorder in women and men, vasomotor symptoms; hot flashes